Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025

COGNITION THERAPEUTICS INC

Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.
Cash and equivalents $29.9M at Dec 31, 2023; NIA grant funds of $67.5M remain available.
March 2024 follow-on offering raised ~$10.4M net, extending cash runway through May 2025.
Topline results from Phase 2 SHINE study (Alzheimer's) expected mid-2024; SHIMMER (DLB) in 2H2024.
R&D expenses rose to $37.2M from $30.3M, mainly due to Phase 2 trial activities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.

Period: the year ended December 31, 2023
Net income: $25.8 million
EPS: $(0.86) per basic and diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-038686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.